3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug
By
Kimberly Bonvissuto
Jun 11, 2021
Three members of a Food & Drug Administration advisory panel resigned this week over the agency’s controversial decision on Monday to approve a novel therapy for Alzheimer’s disease.
FDA head asks for investigation into Alzheimer’s disease drug approval
Jul 12, 2021
The request follows reports that Biogen and the FDA held off-the-books meetings before the drug’s approval that may have violated FDA protocol.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
FDA approves first treatment for Alzheimer’s in 18 years
By
Kimberly Bonvissuto
Jun 07, 2021
The first novel therapy for Alzheimer’s disease in almost two decades was approved today by the Food & Drug Administration.
Health habits’ connection to dementia in the spotlight as new year begins
By
Lois A. Bowers
Jan 04, 2022
An update to the National Plan to Address Alzheimer’s Disease, as well as news of potential treatments and a finding that “astonished” researchers add up to promising news to start the new...